7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
Mayank kaushik journal club MPC302JC [Autosaved].pptx
1. Formulation and evaluation of novel
controlled release of topical pluronic
lecithin organogel of mefenamic acid.
1
Supervised By:
Dr. Kaisar Raza Sir
Assistant Professor
Presented by :
Mayank Kaushik
Enroll.no: 2020mpp005
Department of Pharmacy
School of Chemical Sciences and Pharmacy
Central University of Rajasthan
4. Mefenamic acid is a drug of NSAIDs category having
antiinflammatory and analgesic activity. It is used in management of
pain and inflammation, swelling and uterine contractions by
inhibition of prostaglandin synthesis. Conventional oral dosage
form of mefenamic acid is available in the form of capsules but like
other NSAIDs, mefenamic acid is also prone to cause
gastrointestinal ulceration, rashes and intestinal bleeding when
administered by oral route.
PLO gels are nonirritant and biocompatible composed of
phospholipid (lecithin) as surfactant, an organic solvent as outer
continuous phase and an aqueous polar phase/solvent. The
entangled reverse micelles forms a 3D network which entraps the
outer continuous nonpolar phase and immobilizes it turning into a
viscous gelby self-association of individual gelator molecules.
PLO gel formulation of mefenamic acid for anti-inflammatory
activity using in vivo method in rat model.
4
INTRODUCTION
5. To develop PLO gel formulation of mefenamic acid for anti-
inflammatory activity using in vivo method in rat model
5
OBJECTIVE
7. Oil phase: The oil phase is prepared by taking a measured amount of
lecithin and sorbic acid in IPM as a solvent. The above mixture was
kept at room temperature for 12 h to ensure complete dissolution of
lecithin and sorbic acid in IPM.
Aqueous phase: Aqueous phase was prepared by dissolving weighed
quantity of pluronic F-127 and potassium sorbate and menthol in cold
water. The mixture was kept below 4 C in refrigerator for 12 h for
complete dissolution of pluronic F-127.
Next day, gel was prepared by adding slowly oil phase to aqueous
phase at a high shear using mechanical stirrer so that a uniformly
dispersed microemulsion is formed. Drug was incorporated in oil
phase by making a paste with polyethylene glycol 400 before mixing
with pluronic phase .
7
METHOD
9. Figure 1. Carrageenan induced paw edema test 9
RESULT AND DISCUSSION
10. Figure 2. Light microscope structure at 10 40 resolution (1) and SEM
image at 10 1000 resolution of organogel formulation 10
RESULT AND DISCUSSION
11. Table 2. Evaluation parameters of organogel formulations (F1–F10)
11
RESULT AND DISCUSSION
12. Figure 3. Viscosity values of formulations from F1 to F10
12
RESULT AND DISCUSSION
13. Table 3. Percentage drug content of organogel
13
RESULT AND DISCUSSION
14. Table 4. Percentage cumulative drug release in 8 h .
14
RESULT AND DISCUSSION
15. Table 5. Kinetic data of release studies for F2 and F3 formulations
15
RESULT AND DISCUSSION
16. Figure 4. Percentage cumulative drug release profile of F1–F5 and
F6–F10 formulations
16
RESULT AND DISCUSSION
17. Table 6. Stability study data of F2 and F3 formulations.
17
RESULT AND DISCUSSION
18. Figure 5. Analgesic activity of mefenamic acid organogel
formulation using Eddy’s hot plate 18
RESULT AND DISCUSSION
19. Figure 6. Anti-inflammatory mefenamic acid organogel using
digital plethysmograph 19
RESULT AND DISCUSSION
20. Table 7. Mean values of paw volume at different time intervals
20
RESULT AND DISCUSSION
21. Therefore, from the study Author concluded that organogels are
novel base for drugs through topical route and could be an alternative
to the marketed diclofenac gel formulations.
F2 formulation may come as a new drug in the market for the
treatment of inflammation after following various phases of clinical
trials and ethical guidelines
21
CONCLUTION
22. Abrol S, Trehan S, Katare OP. (2004). Formulation, characterization,
and in vitro evaluation of silymarin loaded lipid microspheres. Drug
Deliv 11:185–91.
Agrawal V, Gupta AV, Ramteke S, Trivedi P. (2010). Preparation and
evaluation of tubular micelles of pluronic lecithin organogel for
transdermal delivery of sumatriptan. AAPS PharmSciTech 11: 1718–
25.
Arunachalam A, Karthikeyan M, Kumar VD, et al. (2010).
Transdermal drug delivery system: a review. Curr Phar Res 1:70–81.
Ba W, Li Z, Wang L, et al. (2016). Optimization and evaluation of
pluronic lecithin organogels as a transdermal delivery vehicle for
sinomenine. Pharm Dev Technol 21:535–45
22
REFERENCES
